

1. Badger CC, Anasetti C, Davis J, et al. Treatment of malignancy with unmodified antibody. *Pathol Immunopathol Res* 1987;6:419–434.
2. Khazaeli MB, Conry RM, Lobuglio AF. Human immune-response to monoclonal-antibodies. *J Immunother Emphasis Tumor Immunol* 1994;15:42–52.
3. Lee J, Fenton BM, Koch CJ, et al. Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. *Cancer Res* 1998;58:1478–1485.
4. Reichert JM, Dhimolea E. The future of antibodies as cancer drugs. *Drug Discov Today* 2012;17:954–963.
5. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* 1975;256:495–497.
6. Houghton AN, Mintzer D, Cordon-Cardo C, et al. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. *Proc Natl Acad Sci U S A* 1985;82:1242–1246.
7. Steplewski Z, Lubeck MD, Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. *Science* 1983;221:865–867.
8. Trauth BC, Klas C, Peters AM, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. *Science* 1989;245:301–305.
9. Yang XD, Jia XC, Corvalan JR, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. *Cancer Res* 1999;59:1236–1243.
10. Komissarov AA, Calcutt MJ, Marchbank MT, et al. Equilibrium binding studies of recombinant anti-single-stranded DNA Fab. Role of heavy chain complementarity-determining regions. *J Biol Chem* 1996;271:12241–12246.
11. Ghetie V, Popov S, Borvak J, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. *Nat Biotechnol* 1997;15:637–640.
12. LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. *Proc Natl Acad Sci U S A* 1989;86:4220–4224.
13. Kudo T, Saeki H, Tachibana T. A simple and improved method to generate human hybridomas. *J Immunol Methods* 1991;145:119–125.
14. Robinson MK, Weiner LM, Adams GP. Improving monoclonal antibodies for cancer therapy. *Drug Dev Res* 2004;61:172–187.
15. Denlinger CS, Beeram M, Tolcher AW, et al. A phase I/II and pharmacologic study of MM-111 in patients with advanced, refractory HER2-positive (HER2+) cancers. *J Clin Oncol* 2010;28:15.
16. Nagorsen D, Bargou R, Ruttinger D, et al. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. *Leuk Lymphoma* 2009;50:886–891.
17. Goere D, Flament C, Rusakiewicz S, et al. Potent immunomodulatory effects of the trifunctional antibody catumaxomab. *Cancer Res* 2013;73:4663–4673.
18. Jain RK. Transport of molecules in the tumor interstitium: a review. *Cancer Res* 1987;47:3039–3051.
19. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. *Cancer Res* 1990;50:814s–819s.
20. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. *Cancer Res* 1988;48:7022–7032.
21. Jain RK. Transport of molecules across tumor vasculature. *Cancer Metastasis Rev* 1987;6:559–593.
22. Miller RA, Maloney DG, Warnke R, et al. Treatment of B-cell lymphoma with monoclonal anti-idiotypic antibody. *N Engl J Med* 1982;306:517–522.
23. Fujimori K, Covell DG, Fletcher JE, et al. A modeling analysis of monoclonal antibody percolation through tumors: a binding site barrier. *J Nucl Med* 1990;31:1191–1198.
24. Rudnick SI, Lou J, Shaller CC, et al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. *Cancer Res* 2011;71:2250–2259.
25. Thurber GM, Wittup KD. Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. *Cancer Res* 2008;68:3334–3341.
26. Adams GP, Tai MS, McCartney JE, et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. *Clin Cancer Res* 2006;12:1599–1605.
27. Wolff EA, Schreiber GJ, Cosand WL, et al. Monoclonal antibody homodimers: enhanced antitumor activity in nude mice. *Cancer Res* 1993;53:2560–2565.
28. Werlen RC, Lankinen M, Offord RE, et al. Preparation of a trivalent antigen-binding construct using polyoxime chemistry: improved biodistribution and potential for therapeutic application. *Cancer Res* 1996;56:809–815.
29. Shields RL, Namenek AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. *J Biol Chem* 2001;276:6591–6604.
30. Kenanova V, Olafsen T, Crow DM, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoma embryonic antigen single-chain Fv-Fc antibody fragments. *Cancer Res* 2005;65:622–631.
31. McDonagh CF, Huhlov A, Harms BD, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. *Mol Cancer Ther* 2012;11:582–593.
32. Lund J, Takahashi N, Pound JD, et al. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. *J Immunol* 1996;157:4963–4969.
33. Umama P, Jean-Mairet J, Moudry R, et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. *Nat Biotechnol* 1999;17:176–180.
34. Wright A, Morrison SL. Effect of glycosylation on antibody function: implications for genetic engineering. *Trends Biotechnol* 1997;15:26–32.
35. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. *J Clin Oncol* 2012;30:837–842.
36. Raghavan M, Bjorkman PJ. Fc receptors and their interactions with immunoglobulins. *Annu Rev Cell Dev Biol* 1996;12:181–220.
37. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc-gammaRIIIa gene. *Blood* 2002;99:754–758.
38. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. *J Clin Oncol* 2003;21:3940–3947.
39. Koene HR, Kleijer M, Algra J, et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/RH phenotype. *Blood* 1997;90:1109–1114.
40. Gessner JE, Heiken H, Tamm A, et al. The IgG Fc receptor family. *Ann Hematol* 1998;76:231–248.
41. Keler T, Graziano RF, Mandal A, et al. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc-gamma receptor type I-expressing effector cells. *Cancer Res* 1997;57:4008–4014.
42. Weiner LM, Holmes M, Richeson A, et al. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. *J Immunol* 1993;151:2877–2886.
43. Shalaby MR, Shepard HM, Presta L, et al. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. *J Exp Med* 1992;175:217–225.
44. Valone FH, Kaufman PA, Guyre PM, et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. *J Clin Oncol* 1995;13:2281–2292.
45. Weiner LM, Clark JL, Davey M, et al. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc-gammaRIII. *Cancer Res* 1995;55:4586–4593.
46. Liu MA, Kranz DM, Kurnick JT, et al. Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. *Proc Natl Acad Sci U S A* 1985;82:8648–8652.
47. Carter P. Bispecific human IgG by design. *J Immunol Methods* 2001;248:7–15.
48. Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. *Proc Natl Acad Sci U S A* 1995;92:7021–7025.
49. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. *Science* 2008;321:974–977.
50. Fiedler W, Honemann D, Ritter B, et al. Safety and pharmacology of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric, and lung cancer. *Eur J Cancer* 2009;7:136–137.
51. Presta LG. Engineering antibodies for therapy. *Curr Pharm Biotechnol* 2002;3:237–256.
52. Makrides SC. Therapeutic inhibition of the complement system. *Pharmacol Rev* 1998;50:59–87.
53. Walport MJ. Complement, First of two parts. *N Engl J Med* 2001;344:1058–1066.
54. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. *J Immunol* 2003;171:1581–1587.
55. Idusogie EE, Presta LG, Gazzano-Santoro H, et al. Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc. *J Immunol* 2000;164:4178–4184.
56. Sunada H, Magum BE, Mendelsohn J, et al. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. *Proc Natl Acad Sci U S A* 1986;83:3825–3829.
57. Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. *Cancer Cell* 2005;7:301–311.
58. Franklin MC, Carey KD, Vajdos FF, et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. *Cancer Cell* 2004;5:317–328.
59. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. *Cancer Res* 1997;57:4593–4599.
60. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. *Nat Biotechnol* 2005;23:1147–1157.
61. Reiter Y, Pastan I. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. *Trends Biotechnol* 1998;16:513–520.
62. Kreitman RJ, Wang QC, FitzGerald DJ, et al. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. *Int J Cancer* 1999;81:148–155.

63. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. *N Engl J Med* 2001;345:241–247.
64. Pai LH, Bookman MA, Ozols RF, et al. Clinical evaluation of intraperitoneal *Pseudomonas* exotoxin immunocjugate OVB3-PE in patients with ovarian cancer. *J Clin Oncol* 1991;9:2095–2103.
65. Baluna R, Vitetta ES. Vascular leak syndrome: a side effect of immunotherapy. *Immunopharmacology* 1997;37:117–132.
66. Lode HN, Xiang R, Becker JC, et al. Immunocytokines: a promising approach to cancer immunotherapy. *Pharmacol Ther* 1998;80:277–292.
67. Hornick JL, Khawli LA, Hu P, et al. Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors. *Clin Cancer Res* 1999;5:51–60.
68. Lode HN, Xiang R, Duncan SR, et al. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. *Proc Natl Acad Sci U S A* 1999;96:8591–8596.
69. Sharifi J, Khawli LA, Hu P, et al. Generation of human interferon gamma and tumor necrosis factor alpha chimeric TNT-3 fusion proteins. *Hybrid Hybridomics* 2002;21:421–432.
70. Halin C, Niesner U, Villani ME, et al. Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins. *Int J Cancer* 2002;102:109–116.
71. Halin C, Rondini S, Nilsson F, et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. *Nature Biotechnol* 2002;20:264–269.
72. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. *Blood* 2013;121:4854–4860.
73. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. *J Clin Oncol* 2011;29:369–377.
74. Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. *Lancet* 2012;379:1508–1516.
75. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. *Bioconjug Chem* 2010;21:5–13.
76. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. *Br J Clin Pharmacol* 2013;76:248–262.
77. van de Donk NW, Dhimolea E. Brentuximab vedotin. *MAbs* 2012;4:458–465.
78. LoRusso PM, Weiss D, Guardino E, et al. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. *Clin Cancer Res* 2011;17:6437–6447.
79. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. *Clin Cancer Res* 2002;8:1172–1181.
80. Rodriguez M, Coma S, Noe V, et al. Development and effects of immunoliposomes carrying an antisense oligonucleotide against DHFR RNA and directed toward human breast cancer cells overexpressing HER2. *Antisense Nucleic Acid Drug Dev* 2002;12:311–325.
81. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. *J Nucl Med* 2002;43:1507–1529.
82. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. *J Clin Oncol* 1999;17:3793–3803.
83. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. *Proc Natl Acad Sci U S A* 1992;89:4285–4289.
84. Slamon DJ, Clark GM, Wong SC, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987;235:177–182.
85. Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. *J Clin Oncol* 2010;28:92–98.
86. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. *Ann Oncol* 2005;16:273–278.
87. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. *J Clin Oncol* 1996;14:737–744.
88. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. *J Clin Oncol* 1999;17:2639–2648.
89. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin™ (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER21/MBC) markedly increases anticancer activity: a randomized multinational controlled phase III trial. *Proc Am Soc Clin Oncol* 1998;17:A377.
90. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med* 2005;353:1659–1672.
91. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med* 2005;353:1673–1684.
92. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. *Lancet* 2007;369:29–36.
93. Ewer MS, Gibbs HR, Swafford J, et al. Cardiotoxicity in patients receiving trastuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? *Semin Oncol* 1999;26:96–101.
94. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;376:687–697.
95. Gomez-Martin C, Plaza JC, Pazo-Cid R, et al. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. *J Clin Oncol* 2013;31:4445–4452.
96. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. *Cancer Cell* 2002;2:127–137.
97. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med* 2012;366:109–119.
98. Swain SM, Kim SB, Cortes J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol* 2013;14:461–471.
99. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol* 2012;13:25–32.
100. Waksal HW. Role of an anti-epidermal growth factor receptor in treating cancer. *Cancer Metastasis Rev* 1999;18:427–436.
101. Van Cutsem ELL, D'haens C. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (metastatic CRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. Abstract 2. *J Clin Oncol* 2008;26:5s.
102. Bokemeyer CBI, Hartmann JT. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal (metastatic CRC) with FOLFOX with or without cetuximab: The OPUS experience. Abstract 4000. *J Clin Oncol* 2008;26:178s.
103. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. *Lancet* 2009;373:1525–1531.
104. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. *J Clin Oncol* 2010;28:911–917.
105. Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. *Clin Colorectal Cancer* 2006;6:29–31.
106. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 2008;26:1626–1634.
107. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. *Hum Pathol* 1995;26:86–91.
108. Obermair A, Kohlberger P, Bancher-Todesca D, et al. Influence of microvessel density and vascular permeability factor/vascular endothelial growth factor expression on prognosis in vulvar cancer. *Gynecol Oncol* 1996;63:204–209.
109. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. *Arch Surg* 1997;132:541–546.
110. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. *Science* 2005;307:58–62.
111. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004;350:2335–2342.
112. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med* 2006;355:2542–2550.
113. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med* 2007;357:2666.
114. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. *J Clin Oncol* 2005;23:792–799.
115. Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. *J Clin Oncol* 2009;27:3385–3390.
116. Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. *Lancet Oncol* 2013;14:933–942.
117. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. *J Clin Oncol* 2009;27:740–745.

118. Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. *J Clin Oncol* 2011;29:398–405.
119. Krop IE, LoRusso P, Miller KD, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. *J Clin Oncol* 2012;30:3234–3241.
120. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med* 2012;367:1783–1791.
121. Thomas D, Carriere P, Jacobs I. Safety of denosumab in giant-cell tumour of bone. *Lancet Oncol* 2012;11:815.
122. Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. *Lancet Oncol* 2013;14:901–908.
123. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. *Lancet* 2011;377:813–822.
124. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. *J Clin Oncol* 2011;29:1125–1132.
125. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol* 2010;28:5132–5139.
126. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med* 2009;361:745–755.
127. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. *J Clin Oncol* 2008;26:4875–4882.
128. Maloney D, Grillo-López A, Bodkin D, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. *J Clin Oncol* 1997;15:3266–3274.
129. Maloney D, Grillo-López A, White C, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. *Blood* 1997;90:2188–2195.
130. Shan D, Ledbetter J, Press O. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. *Cancer Immunol Immunother* 2000;48:673–683.
131. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. *Blood* 1998;92:1927–1932.
132. Czuczman MS, Grillo-López AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. *J Clin Oncol* 1999;17:268–276.
133. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. *Cancer Biother Radiopharm* 1997;12:177–186.
134. Gribben JC, Freedman A, Woo SD, et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the rearrangement at evaluation and after treatment. *Blood* 1991;78:3275–3280.
135. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol* 2005;23:4117–4126.
136. Kaufmann H, Raderer M, Wohner S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. *Blood* 2004;104:2269–2271.
137. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. *Br J Haematol* 2008;140:36–45.
138. Hooijberg E, Sein JJ, van den Berk PC, et al. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. *Cancer Res* 1995;55:2627–2634.
139. Friedberg JW, Neuberger D, Gribben JC, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. *Br J Haematol* 2002;117:828–834.
140. Khan KD, Emmanouilides C, Benson DM Jr., et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. *Clin Cancer Res* 2006;12:7046–7053.
141. van der Kolk LE, Grillo-López AJ, Baars JW, et al. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. *Leukemia* 2003;17:1658–1664.
142. Warren TL, Dahle CE, Weiner GJ. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. *Clin Lymphoma* 2000;1:57–61.
143. Smith MR, Jin F, Joshi I. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts. *Mol Cancer Ther* 2004;3:1693–1699.
144. Ramanarayanan J, Hernandez-Ilizaliturri FJ, Chanan-Khan A, et al. Proapoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. *Br J Haematol* 2004;127:519–530.
145. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. *Cancer Cell* 2006;10:389–399.
146. Paoluzzi L, Gonen M, Gardner JR, et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in vitro and in vivo models of B-cell lymphoma. *Blood* 2008;111:5350–5358.
147. Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. *Proc Natl Acad Sci U S A* 2007;104:19512–19517.
148. Coiffier B, Lepage S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. *Blood* 2008;111:1094–1100.
149. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. *J Clin Oncol* 2010;28:1749–1755.
150. Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMM106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. *Clin Cancer Res* 2004;10:2868–2878.
151. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. *Nat Biotechnol* 2012;30:631–637.
152. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. *J Clin Oncol* 2012;30:2190–2196.
153. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. *J Clin Oncol* 2012;30:2183–2189.